Article

Chronic lithium attenuates dopamine D1-receptor mediated increases in acetylcholine release in rat frontal cortex.

Department of Psychiatry, University of British Columbia, Vancouver, Canada.
Psychopharmacology (Impact Factor: 3.99). 06/1996; 125(2):162-7. DOI: 10.1007/BF02249415
Source: PubMed

ABSTRACT The effects of chronic lithium treatment on methylphenidate-, D1 dopamine receptor agonist (A-77636)-, and tactile stimulation-induced increases in frontal cortical acetylcholine release were studied in the rat using in vivo brain microdialysis. Cortical acetylcholine release in control rats was maximally stimulated by methylphenidate (1.25 and 2.5 mg/kg) to 173% and 212% above baseline, respectively. The effect of methylphenidate (2.5 mg/kg) was blocked by pretreatment with the dopamine D1 receptor antagonist SCH 23390 (0.3 mg/kg). Chronic treatment with lithium chloride (3-4 weeks) produced plasma lithium concentrations of 0.45 +/- 0.02 meq/l. Chronic lithium significantly reduced increases in cortical acetylcholine release produced by methylphenidate. Stimulation of dopamine D1 receptors with the full D1 receptor agonist A-77636 (0.73 mg/kg) increased cortical acetylcholine release. Chronic lithium significantly reduced this effect of A-77636. In contrast, lithium failed to influence the increases of cortical acetylcholine release produced by tactile stimulation. These results suggest that while lithium does not influence normal, arousal-related increase in cortical acetylcholine release, this ion selectively attenuates dopamine mediated increases and/or abnormally large increases, which in the present circumstances were pharmacologically induced. The relevance of these findings to the antimanic actions of lithium is discussed.

0 Bookmarks
 · 
241 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the present study, we employed in vivo microdialysis in the frontal cortex of the awake rat to investigate the effects of acute and short-term (twice daily, 3 days) lithium chloride administration (1, 2, and 4 meq/kg, s.c.) on local dialysate glutamate and GABA levels. Acute lithium (1 meq/kg) failed to influence cortical glutamate levels while the higher (2 and 4 meq/kg) doses increased (+38 ± 6% of basal levels) and reduced (-27 ± 4%) cortical glutamate levels, respectively. Cortical GABA levels were affected by acute lithium only at the highest 4 meq/kg dose (+62 ± 6%). Furthermore, these effects were prevented by tetrodotoxin (1 μM) and low-calcium (0.2 mM) medium perfusion. Following short-term administration, lithium increased (+58 ± 4%) cortical dialysate glutamate levels at the 1 meq/kg dose, was ineffective at 2 meq/kg, while the effect of the 4 meq/kg dose was similar to that observed after acute administration. Interestingly, intracortical perfusion with the GABAB receptor antagonist CGP 35348 (100 μM) reversed the acute lithium (4 meq/kg)-induced decrease in glutamate levels. Taken together, these findings indicate a differential dose and duration dependent effect of lithium on cortical dialysate glutamate levels involving both a direct enhancement and an indirect inhibition that is mediated via an activation of local GABAB receptor. These findings may be relevant for the therapeutic effects of the drug. Synapse 38:355–362, 2000. © 2000 Wiley-Liss, Inc.
    Synapse 12/2000; 38(3):355 - 362. DOI:10.1002/1098-2396(20001201)38:3<355::AID-SYN15>3.0.CO;2-E · 2.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lithium is considered to be the first choice mood stabilizer in recurrent mood disorders. Its widespread and large-scale use is the result of its proven efficacy. In spite of this fact, patients have been observed to show a variable response to lithium treatment: in some cases it is completely effective in preventing manic or depressive relapses, while in other cases it appears to show no influence on the disease course. The possible definition of a genetic liability profile for adverse effects and efficacy will be of great help, as lithium therapy needs at least 6 months to be effective in stabilizing mood disorders. During the last few years, a number of groups have reported possible liability genes. Lithium long-term prophylactic efficacy has been associated with serotonin transporter protein, tryptophan hydroxylase and inositol polyphosphate 1-phosphatase variants. A number of other candidate genes and anonymous markers did not yield positive associations. Therefore, even if some positive results have been reported, no unequivocal susceptibility gene for lithium efficacy has been identified. Although the available data may not currently allow a meaningful prediction of lithium response, future research is aimed at the development of individualized treament of mood disorders, including the possibility of ‘pharmacological genetic counseling’.
    American Journal of PharmacoGenomics 01/2003; 3(1). DOI:10.2165/00129785-200303010-00004
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: The effects of chronic lithium exposure on spatial memory in rats remain controversial. In this study a time course of the effects of lithium, administered systemically, on spatial memory acquisition in Morris water maze was investigated. Material and Methods: Lithium (600 mg/L) was administered to four groups of rats in their drinking water; the first group of animals received lithium for one week, the second group for two weeks, the third group for three weeks, and the fourth group for four weeks. As controls, four groups of animals received only normal drinking water for the same period of time. Toward the end of their lithium or water treatment, all animals were trained for four days; each day included one block and each block contained four trials. Test trials were conducted 48 hrs after completion of the lithium treatment. Escape latency, traveled distance and swimming speed were evaluated during testing trials. Brain tissues from animals were processed according to the standard protocols for immunohistochemical analysis. Results: Lithium treatment decreased escape latency and traveled distance, but not swimming speed, compared with controls, suggesting significant spatial memory acquisition enhancement by lithium. Quantitative analysis showed that lithium, particularly after four weeks of exposure, significantly increased the number and density of immunostained ChAT-containing (choline acetyltransferase) neurons in the medial septal area in comparison with control groups. There was also a significant correlation between the number of immunostained ChAT neurons and behavioral measures. Conclusion: These results suggest that chronic oral administration of lithium causes spatial memory acquisition improvement in rats and an increase in ChAT immunostaining levels in medial septal nuclei.